Literature DB >> 23722227

Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells.

Giada Poli1, Daniele Guasti, Elena Rapizzi, Rossella Fucci, Letizia Canu, Alessandra Bandini, Nicoletta Cini, Daniele Bani, Massimo Mannelli, Michaela Luconi.   

Abstract

At present, mitotane (MTT) represents the first-line pharmacological approach for the treatment of advanced adrenocortical carcinoma (ACC). Despite clear evidence that the drug can reduce the clinical signs of steroid excess in secreting ACC, the mechanism mediating the possible toxic effect of MTT on tumor cells still remains obscure. This study investigated the intracellular events underlying the toxic effect of MTT by studying qualitative and quantitative alterations in mitochondrial morphology and functions in human adrenocortical cancer cell lines, H295R and SW13. Increasing concentrations of MTT resulted in rapid intracellular accumulation and conversion of the drug. Cytostatic and cytotoxic effects were evident at doses corresponding to the therapeutic window (30-50 μM) through an apoptotic mechanism involving caspase 3/7. Electron microscopic analysis of cell mitochondria displayed MTT-induced dose- and time-dependent alterations in the morphology of the organelle. These alterations were characterized by a marked swelling and a decrease in the number of respiratory cristae, accompanied by a significant depolarization of the mitochondrial membrane potential, finally leading to the disruption of the organelle. A drastic reduction of oxygen consumption was observed due to mitochondrial membrane damage, which was accompanied by a decrease in the levels of VDAC1 integral membrane channel. These findings contribute to better understand the intracellular mechanism of action of MTT in ACC cells, showing that its cytotoxic effect seems to be mainly mediated by an apoptotic process activated by the disruption of mitochondria.

Entities:  

Keywords:  adrenal cortex; carcinoma; intracellular signalling

Mesh:

Substances:

Year:  2013        PMID: 23722227     DOI: 10.1530/ERC-13-0150

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  15 in total

1.  The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.

Authors:  Ségolène Hescot; Angelo Paci; Atmane Seck; Abdelhamid Slama; Say Viengchareun; Séverine Trabado; Sylvie Brailly-Tabard; Abir Al Ghuzlan; Jacques Young; Eric Baudin; Marc Lombès
Journal:  Horm Cancer       Date:  2014-07-16       Impact factor: 3.869

2.  Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.

Authors:  Teresa Gagliano; Erica Gentilin; Katiuscia Benfini; Carmelina Di Pasquale; Martina Tassinari; Simona Falletta; Carlo Feo; Federico Tagliati; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2014-08-06       Impact factor: 3.633

3.  ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.

Authors:  Yunhui Cheng; Raili Emilia Kerppola; Tom Klaus Kerppola
Journal:  Endocr Relat Cancer       Date:  2016-02-03       Impact factor: 5.678

4.  Adrenocortical carcinoma: modern management and evolving treatment strategies.

Authors:  Lucas A McDuffie; Rachel D Aufforth
Journal:  Int J Endocr Oncol       Date:  2016-04-08

5.  Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches.

Authors:  Ségolène Hescot; Larbi Amazit; Marie Lhomme; Simon Travers; Anais DuBow; Stephanie Battini; Geoffrey Boulate; Izzie Jacques Namer; Anne Lombes; Anatol Kontush; Alessio Imperiale; Eric Baudin; Marc Lombes
Journal:  Oncotarget       Date:  2017-07-04

6.  Metformin as a new anti-cancer drug in adrenocortical carcinoma.

Authors:  Giada Poli; Giulia Cantini; Roberta Armignacco; Rossella Fucci; Raffaella Santi; Letizia Canu; Gabriella Nesi; Massimo Mannelli; Michaela Luconi
Journal:  Oncotarget       Date:  2016-08-02

7.  Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma.

Authors:  Wen-Hao Xu; Junlong Wu; Jun Wang; Fang-Ning Wan; Hong-Kai Wang; Da-Long Cao; Yuan-Yuan Qu; Hai-Liang Zhang; Ding-Wei Ye
Journal:  Front Genet       Date:  2019-09-11       Impact factor: 4.599

8.  Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells.

Authors:  Athanasios Bikas; Kirk Jensen; Aneeta Patel; John Costello; Gregory Kaltsas; Victoria Hoperia; Leonard Wartofsky; Kenneth Burman; Vasyl Vasko
Journal:  Int J Oncol       Date:  2019-05-16       Impact factor: 5.650

9.  The effects of mitotane and 1α,25-dihydroxyvitamin D3 on Wnt/beta-catenin signaling in human adrenocortical carcinoma cells.

Authors:  B Rubin; C Pilon; R Pezzani; A Rebellato; F Fallo
Journal:  J Endocrinol Invest       Date:  2019-10-05       Impact factor: 4.256

10.  Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Yongquan Tang; Zhihong Liu; Zijun Zou; Jiayu Liang; Yiping Lu; Yuchun Zhu
Journal:  Biomed Res Int       Date:  2018-06-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.